FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022997118> ?p ?o ?g. }

• W2022997118 endingPage "349" @default.
• W2022997118 startingPage "349" @default.
• W2022997118 abstract "Back to table of contents Previous article Next article LETTERFull AccessA Novel View on the Pharmacodynamics of Rosiglitazone and Introducing Some Potential Drugs in Ameliorating Alzheimer’s DiseaseShahriar Gharibzadeh M.D., Ph.D.Sayed Shahabuddin Hoseini M.D.,Shahriar Gharibzadeh M.D., Ph.D.Search for more papers by this authorSayed Shahabuddin Hoseini M.D.Search for more papers by this author,Published Online:1 Jul 2007https://doi.org/10.1176/jnp.2007.19.3.349AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail SIR: Alzheimer’s disease is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory deterioration, progressive impairment of daily living activities, and a variety of neuropsychiatric symptoms and behavioral disturbances. Increasing evidence shows that neurotoxicity is mediated by CNS inflammatory processes, which involve activation of the microglia by the amyloid-beta, leading to the release of proinflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha). Neurotoxic processes mediated by these cytokines may include direct neuronal death by enhancement of apoptosis, decreased synaptic function, and inhibition of hippocampal neurogenesis. 1 Rosiglitazone is used in some studies for improving the symptoms of Alzheimer’s disease but there is controversy about its mechanism of action. 2 There is evidence that shows the effect of rosiglitazone in reducing IL-6. 3 Although a study has shown that rosiglitazone cannot reduce IL-6, 4 it seems that this study was not maintained long enough to determine this effect. In addition, a study showed that poor sleep is associated with higher interleukin-6 in older caregivers of people with Alzheimer’s disease. 5According to aforementioned studies, we hypothesize that one of the mechanisms of action of rosiglitazone in ameliorating Alzheimer’s disease is reducing IL-6. Moreover, it seems that this drug can improve the sleep of people with Alzheimer’s disease.Prescribing other IL-6 reducers as clenbuterol may be a good treatment for Alzheimer’s disease. On the other hand, TNF-alpha antagonists, like thalidomide, infliximab, etanercept, and adalimumab, may be effective in Alzheimer’s disease.Surely, clinical trials are needed to validate our hypothesis.Neuromuscular Systems Laboratory, Department of Biomedical Engineering, Amirkabir University of Technology, Tehran, IranReferences1 . Rosenberg PB: Clinical aspects of inflammation in Alzheimer’s disease. Int Rev Psychiatry 2005; 17:503–514Google Scholar2 . Watson GS, Cholerton BA, Reger MA, et al: Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005; 13:950–958Google Scholar3 . Esposito K, Ciotola M, Carleo D, et al: Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 2006; 29:1071–106Google Scholar4 . Hetzel J, Balletshofer B, Rittig K, et al: Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 2005; 25:1804–1809Google Scholar5 . von Kanel R, Dimsdale JE, Ancoli-Israel S, et al: Poor sleep is associated with higher plasma proinflammatory cytokine interleukin-6 and procoagulant marker fibrin D-dimer in older caregivers of people with Alzheimer’s disease. J Am Geriatr Soc 2006; 54:431–437Google Scholar FiguresReferencesCited byDetailsCited byNone Volume 19Issue 3 Summer, 2007Pages 349-349 Metrics PDF download History Published online 1 July 2007 Published in print 1 July 2007" @default.
• W2022997118 created "2016-06-24" @default.
• W2022997118 creator A5007653799 @default.
• W2022997118 creator A5049918969 @default.
• W2022997118 date "2007-07-01" @default.
• W2022997118 modified "2023-09-26" @default.
• W2022997118 title "A Novel View on the Pharmacodynamics of Rosiglitazone and Introducing Some Potential Drugs in Ameliorating Alzheimer’s Disease" @default.
• W2022997118 cites W1582760258 @default.
• W2022997118 cites W1979480974 @default.
• W2022997118 cites W1995564836 @default.
• W2022997118 cites W2033823029 @default.
• W2022997118 cites W2071567967 @default.
• W2022997118 cites W2143991719 @default.
• W2022997118 cites W2149901653 @default.
• W2022997118 cites W2166853536 @default.
• W2022997118 cites W2169668693 @default.
• W2022997118 doi "https://doi.org/10.1176/jnp.2007.19.3.349" @default.
• W2022997118 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17827434" @default.
• W2022997118 hasPublicationYear "2007" @default.
• W2022997118 type Work @default.
• W2022997118 sameAs 2022997118 @default.
• W2022997118 citedByCount "0" @default.
• W2022997118 crossrefType "journal-article" @default.
• W2022997118 hasAuthorship W2022997118A5007653799 @default.
• W2022997118 hasAuthorship W2022997118A5049918969 @default.
• W2022997118 hasConcept C111113717 @default.
• W2022997118 hasConcept C112705442 @default.
• W2022997118 hasConcept C126322002 @default.
• W2022997118 hasConcept C134018914 @default.
• W2022997118 hasConcept C15744967 @default.
• W2022997118 hasConcept C164027704 @default.
• W2022997118 hasConcept C169760540 @default.
• W2022997118 hasConcept C2776914184 @default.
• W2022997118 hasConcept C2776925932 @default.
• W2022997118 hasConcept C2779134260 @default.
• W2022997118 hasConcept C2779491297 @default.
• W2022997118 hasConcept C2779830541 @default.
• W2022997118 hasConcept C2780152017 @default.
• W2022997118 hasConcept C29730261 @default.
• W2022997118 hasConcept C502032728 @default.
• W2022997118 hasConcept C555293320 @default.
• W2022997118 hasConcept C71924100 @default.
• W2022997118 hasConcept C98274493 @default.
• W2022997118 hasConceptScore W2022997118C111113717 @default.
• W2022997118 hasConceptScore W2022997118C112705442 @default.
• W2022997118 hasConceptScore W2022997118C126322002 @default.
• W2022997118 hasConceptScore W2022997118C134018914 @default.
• W2022997118 hasConceptScore W2022997118C15744967 @default.
• W2022997118 hasConceptScore W2022997118C164027704 @default.
• W2022997118 hasConceptScore W2022997118C169760540 @default.
• W2022997118 hasConceptScore W2022997118C2776914184 @default.
• W2022997118 hasConceptScore W2022997118C2776925932 @default.
• W2022997118 hasConceptScore W2022997118C2779134260 @default.
• W2022997118 hasConceptScore W2022997118C2779491297 @default.
• W2022997118 hasConceptScore W2022997118C2779830541 @default.
• W2022997118 hasConceptScore W2022997118C2780152017 @default.
• W2022997118 hasConceptScore W2022997118C29730261 @default.
• W2022997118 hasConceptScore W2022997118C502032728 @default.
• W2022997118 hasConceptScore W2022997118C555293320 @default.
• W2022997118 hasConceptScore W2022997118C71924100 @default.
• W2022997118 hasConceptScore W2022997118C98274493 @default.
• W2022997118 hasIssue "3" @default.
• W2022997118 hasLocation W20229971181 @default.
• W2022997118 hasLocation W20229971182 @default.
• W2022997118 hasOpenAccess W2022997118 @default.
• W2022997118 hasPrimaryLocation W20229971181 @default.
• W2022997118 hasRelatedWork W2035878924 @default.
• W2022997118 hasRelatedWork W2058815861 @default.
• W2022997118 hasRelatedWork W2333306266 @default.
• W2022997118 hasRelatedWork W2390949632 @default.
• W2022997118 hasRelatedWork W2914743334 @default.
• W2022997118 hasRelatedWork W3045733764 @default.
• W2022997118 hasRelatedWork W3107895302 @default.
• W2022997118 hasRelatedWork W4296743062 @default.
• W2022997118 hasRelatedWork W4306247679 @default.
• W2022997118 hasRelatedWork W4309467168 @default.
• W2022997118 hasVolume "19" @default.
• W2022997118 isParatext "false" @default.
• W2022997118 isRetracted "false" @default.
• W2022997118 magId "2022997118" @default.
• W2022997118 workType "article" @default.